How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,869 results for

Chronic Myelogenous Leukemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient Full Text available with Trip Pro

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient Occurrence of two different hematological malignancies is very infrequent, and it is nevertheless important not to neglect basic examinations in patients follow-up. A 65-year-old patient was referred to our institution for his chronic lymphocytic leukemia (CLL) checkup; we report the different steps leading to the diagnosis of a second hematological malignancy.

2018 Clinical Case Reports

2. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia

Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic (...) record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML) have an overproduction of partially mature white blood cells of the myeloid

2016 Health Technology Assessment (HTA) Database.

3. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia (...) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML

2016 Health Technology Assessment (HTA) Database.

4. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies (...) on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale

2016 Health Technology Assessment (HTA) Database.

5. Chronic Myelogenous Leukemia Treatment (PDQ®): Patient Version

Chronic Myelogenous Leukemia Treatment (PDQ®): Patient Version Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet (...) ]. Bethesda (MD): ; 2002-. Search term Chronic Myelogenous Leukemia Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: October 30, 2019. This PDQ cancer information summary has current information about the treatment of chronic myelogenous leukemia. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries

2018 PDQ - NCI's Comprehensive Cancer Database

6. Chronic myelogenous leukaemia

Chronic myelogenous leukaemia Chronic myelogenous leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic myelogenous leukaemia Last reviewed: February 2019 Last updated: October 2018 Summary Malignant clonal disorder of haematopoietic stem cells. At presentation, one third of patients may be asymptomatic; if present, symptoms typically include malaise, fever, weight loss, abdominal discomfort, and night (...) sweats. Splenomegaly is the most common physical finding; nearly all patients will have elevated WBC count. Presence of Philadelphia chromosome and /or molecular demonstration of the BCR-ABL transcript confirms diagnosis. Treatment with a BCR-ABL tyrosine kinase inhibitor gives long-term remission without significant adverse events in most patients. Definition Chronic myelogenous leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell that results in marked myeloid hyperplasia

2018 BMJ Best Practice

7. Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia Full Text available with Trip Pro

Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia 29998167 2018 11 14 2341-4545 25 4 2018 Jun GE Portuguese journal of gastroenterology GE Port J Gastroenterol Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia. 198-200 10.1159/000481538 Perdigoto David N DN Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Lopes Sandra S Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal (...) . Portela Francisco F Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Cipriano Maria Augusta MA Pathology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Tomé Luís L Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. eng Journal Article 2017 10 28 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Chronic myelogenous leukemia Colitis Dasatinib Hematochezia 2017 07 06 2017 08 22 2018 7 13 6 0 2018 7

2017 GE Portuguese journal of gastroenterology

8. Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia The safety and scientific validity of this study is the responsibility of the study sponsor

2018 Clinical Trials

9. Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia Full Text available with Trip Pro

Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 (...) and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC

2018 Nature medicine

10. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. (Abstract)

Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. The authors examined Medicare spending and patient spending in older patients with chronic myelogenous leukemia (CML) over the first 5 years from the time of CML diagnosis in the tyrosine kinase inhibitor (TKI) era.Medicare beneficiaries with CML who were diagnosed between 2007 and 2012 at age >65 years were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (805

2019 Cancer

11. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. Full Text available with Trip Pro

Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib.A 40-year-old man with chronic myeloid leukemia was referred to our hospital because of proteinuria 1 month after dasatinib therapy was introduced. A percutaneous kidney

2019 BMC Nephrology

12. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. (Abstract)

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. Late mortality was investigated in patients with chronic myelogenous leukemia (CML) who underwent blood or bone marrow transplant (BMT) with or without prior tyrosine kinase inhibitor (TKI) therapy.By using data from the Blood or Marrow Transplant Survivor Study, the authors examined late mortality (...) included chronic graft-versus-host disease (hazard ratio [HR], 2.8; 95% CI, 1.8-4.4) and busulfan/cyclophosphamide conditioning (HR, 0.5; 95% CI, 0.3-0.9; reference, total body irradiation/cyclophosphamide conditioning). The 20-year cumulative incidence of CML-related and non-CML-related mortality was 6% and 36%, respectively, for the entire cohort. Both CML-related mortality (HR, 1.0; 95% CI, 0.1-12.6) and non-CML-related mortality (HR, 1.3; 95% CI, 0.6-3.1) were comparable for those with and without

2019 Cancer

13. Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: A case report. Full Text available with Trip Pro

Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: A case report. Chronic myelogenous leukemia (CML), a clonal disorder of pluripotent stem cell, rarely presents with bleeding in chronic phase due to the function preservation of the platelets. Factor (F) XIII deficiency, an extremely rare hemorrhagic disease, can cause fatal bleeding, which has been previously described in autoimmune disorders and leukemias.A

2019 Medicine

14. Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia Full Text available with Trip Pro

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia The availability of kinase and other small-molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia.

2017 Clinical Case Reports

15. Chronic myelogenous leukaemia

Chronic myelogenous leukaemia Chronic myelogenous leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic myelogenous leukaemia Last reviewed: February 2019 Last updated: October 2018 Summary Malignant clonal disorder of haematopoietic stem cells. At presentation, one third of patients may be asymptomatic; if present, symptoms typically include malaise, fever, weight loss, abdominal discomfort, and night (...) sweats. Splenomegaly is the most common physical finding; nearly all patients will have elevated WBC count. Presence of Philadelphia chromosome and /or molecular demonstration of the BCR-ABL transcript confirms diagnosis. Treatment with a BCR-ABL tyrosine kinase inhibitor gives long-term remission without significant adverse events in most patients. Definition Chronic myelogenous leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell that results in marked myeloid hyperplasia

2017 BMJ Best Practice

16. Chronic Myelogenous Leukemia Treatment (PDQ®): Health Professional Version

Chronic Myelogenous Leukemia Treatment (PDQ®): Health Professional Version Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries (...) [Internet]. Bethesda (MD): ; 2002-. Search term Chronic Myelogenous Leukemia Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: February 8, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of chronic myelogenous leukemia. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines

2017 PDQ - NCI's Comprehensive Cancer Database

17. Polyethylene Glycol Interferon Alfa-2b Versus Interferon Alfa-2b in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026/MK-4031-001)

Polyethylene Glycol Interferon Alfa-2b Versus Interferon Alfa-2b in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026/MK-4031-001) Polyethylene Glycol Interferon Alfa-2b Versus Interferon Alfa-2b in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026/MK-4031-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Polyethylene Glycol Interferon Alfa-2b Versus Interferon Alfa-2b in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026/MK-4031-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2018 Clinical Trials

18. Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells Full Text available with Trip Pro

Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells Chronic myelogenous leukemia (CML) caused by hematopoietic stem cells expressing the Bcr-Abl fusion gene may be controlled by Bcr-Abl tyrosine kinase inhibitors (TKIs). However, CML-initiating cells are resistant to TKIs and may persist as minimal residual disease. We demonstrate that mice deficient in Sipa1, which encodes Rap1 GTPase-activating protein, rarely develop CML upon transfer

2018 Nature communications

19. Chronic myelogenous leukemia on target Full Text available with Trip Pro

Chronic myelogenous leukemia on target Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro-leukemic activity of the BCR-ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off-target effects, treatment-induced drug resistance, and the limited effect of these drugs on CML stem cells (SCs) are major drawbacks frequently resulting in insufficient or unsustainable treatment. Therefore, intense research efforts have

2018 Cancer medicine

20. Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib Full Text available with Trip Pro

Pretreatment evaluation of fluorescence resonance energy transfer‐based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib Tyrosine kinase inhibitors (TKI) are used for primary therapy in patients with newly diagnosed CML. However, a reliable method for optimal selection of a TKI from the viewpoint of drug sensitivity of CML cells has not been established. We have developed a FRET-based drug sensitivity test in which a CrkL-derived fluorescent (...) biosensor efficiently quantifies the kinase activity of BCR-ABL of living cells and sensitively evaluates the inhibitory activity of a TKI against BCR-ABL. Here, we validated the utility of the FRET-based drug sensitivity test carried out at diagnosis for predicting the molecular efficacy. Sixty-two patients with newly diagnosed chronic phase CML were enrolled in this study and treated with dasatinib. Bone marrow cells at diagnosis were subjected to FRET analysis. The ΔFRET value was calculated

2018 Cancer science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>